Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Multi-kinase inhibitor (VEGFR/FGFR/RET/KIT)

Lenvatinib (Specialist drug)

Brand names: Kisplyx, Lenvima

Lenvatinib is an oral multitargeted tyrosine kinase inhibitor used as a specialist treatment for differentiated thyroid cancer, hepatocellular carcinoma and renal cell carcinoma (the latter in combination). It is taken once daily under oncology supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits multiple receptor tyrosine kinases, including VEGFR, FGFR, PDGFR, RET and KIT, blocking tumour angiogenesis and proliferation.

Prescribing in practice

  • Hypertension is very common and can be severe; blood pressure must be controlled before starting and monitored closely thereafter.
  • Risks include haemorrhage, arterial thromboembolism, QT prolongation, proteinuria, hepatotoxicity and impaired wound healing.
  • Withhold around surgery and manage thyroid function, as hypothyroidism and increased thyroid hormone requirements can occur.

Monitoring

Monitor blood pressure, urinary protein, liver and thyroid function, and electrolytes during treatment.

Counselling the patient

  • Monitor blood pressure as advised and report readings that are persistently high.
  • Report any bleeding, chest pain, severe headache or sudden weakness promptly.
  • Tell the team before any planned surgery or dental procedure.

Evidence & guidelines

The SELECT trial showed improved progression-free survival with lenvatinib in radioiodine-refractory differentiated thyroid cancer.

Reference: NICE TA535/TA551/TA519; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways